866-997-4948(US-Canada Toll Free)

Revatio (sildenafil)- Analysis and Estimates from 2005 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 41 Pages


GlobalDatas pharmaceuticals report, Revatio (sildenafil)Analysis and Estimates from 2005 to 2020 provides Revatio sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2005-2020). The report also includes information on Pulmonary Arterial Hypertension market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Revatio including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Revatio including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2005-2020 for Revatio in the seven major markets
Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Introduction 5
2.1 Pulmonary Arterial Hypertension 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 6
2.3 Etiology 6
2.3.1 Scleroderma 6
2.3.2 Sickle Cell Disease 6
2.3.3 HIV/AIDS 6
2.3.4 Drug Abuse and Toxins 6
2.4 Economic Impact of PAH 6
2.5 GlobalData Report Guidance 7

3 Pulmonary Arterial Hypertension (PAH): Market Characterization 8
3.1 PAH Market 8
3.2 PAH Market Forecasts and CAGR 9
3.3 PAH Market : Drivers and Restraints 9
3.3.1 Drivers 10
3.3.2 Barriers 11

4 Classification of PAH 12
4.1 Classification Based on Cause and Clinical Presentation 12
4.1.1 Idiopathic PAH 12
4.1.2 Familial PAH 12
4.1.3 Drug Induced PAH 12
4.1.4 PAH Associated with Other Conditions 12
4.1.5 PAH Associated with Significant Venous or Capillary Involvement 12
4.2 Symptomatic Profile of PAH 12

5 Evolution of PAH Treatments 13

6 Medications 13
6.1 Prostanoids 13
6.1.1 Epoprostenol 14
6.1.2 Treprostinil 14
6.1.3 Iloprost 14
6.1.4 Beraprost 14
6.2 Endothelin Receptor Antagonists 14
6.2.1 Bosentan 14
6.2.2 Ambrisentan 14
6.2.3 Sitaxsentan 14
6.3 Phosphodiesterase Type 5 Inhibitors 15
6.3.1 Sildenafil 15
6.3.2 Tadalafil 15
6.4 Surgical Treatments 15
6.5 Investigational Combination Regimens 15
6.6 New Targets for PAH Therapy 16

7 Market Share by Class in PAH 18

8 Revatio (sildenafil) 19
8.1 Introduction 19
8.2 Mechanism of Action 19
8.3 Clinical Studies 19
8.3.1 Study 1 19
8.3.2 Study 2 22
8.4 Approval History of Revatio 23
8.5 Factors Affecting Sales of Revatio 23
8.5.1 First Oral Medicine for Mildly Symptomatic PAH 23
8.5.2 Competition from Adcirca 23
8.5.3 Dosing Compliance 23
8.5.4 Dual Routes of Administration 24
8.5.5 Revatio Effectiveness in PAH patients 24
8.5.6 High Competition and Patent Expiry 24
8.6 Drug Evaluation 24
8.6.1 Drug Risk Benefit Score 24
8.6.2 Intensity of Competition 25
8.7 Sales Estimates 25
8.7.1 Target Patient Pool for Revatio 25
8.7.2 Dosing 26
8.7.3 Market Penetration 26
8.7.4 Annual Cost of Therapy 26
8.7.5 Sales Projections of Revatio 27

9 PAH Market: Appendix 36
9.1 Market Definitions 36
9.2 List of Abberiviations 36
9.3 Research Methodology 37
9.3.1 Coverage 37
9.3.2 Secondary Research 37
9.3.3 Forecasting 37
9.3.4 Number of Patients Approved to take the Drug 38
9.3.5 Net Penetration of Drug 38
9.3.6 Net Annual Dosing 39
9.3.7 Annual Cost of Therapy 39
9.3.8 Primary Research 39
9.3.9 Expert Panels 39
9.4 Drug Sales Estimates Model 40
9.5 Contact Us 40
9.6 Disclaimer 40
9.7 Sources 40

List of Table


Table 1: PAH, Global, Major Marketed Drugs 8
Table 2: PAH, Global, Pipeline (Phase III) 9
Table 3: PAH Drugs Evolution 13
Table 4: Changes from Baseline to Week 12 in Hemodynamic Parameters at Revatio 20mg TID Dose 22
Table 5: Clinical Worsening Events 23
Table 6: Approval of Revatio 23
Table 7: Drug Risk Benefit Score of Revatio 24
Table 8: Annual Cost of Therapy (2010) 26
Table 9: Revatio, Pulmonary Arterial Hypertension, Global, Sales Estimates ($m), 2005-2020 27
Table 10: Revatio, PAH, The US, Sales Estimates ($m), 20052017 28
Table 11: Revatio, PAH, The UK, Sales Estimates ($m), 20052017 29
Table 12: Revatio, PAH, France, Sales Estimates ($m), 20052017 30
Table 13: Revatio, PAH, Germany, Sales Estimates ($m), 20052017 31
Table 14: Revatio, PAH, Italy, Sales Estimates ($m), 20052017 32
Table 15: Revatio, PAH, Spain, Sales Estimates ($m), 20052017 33
Table 16: Revatio, PAH, Japan, Sales Estimates ($m), 2008-2020 34

List of Chart


Figure 1: PAH, Global, Market Size Forecasts ($bn), 20102020 9
Figure 2: PAH, Worldwide, Market Share by Class (%), 2010 18
Figure 3: Change from Baseline in 6-Minute Walk Distance (meter): Mean (95% Confidence Interval) 20
Figure 4: Placebo Corrected Change From Baseline in 6-Minute Walk Distance (meter) by Study Subpopulation: Mean (95% Confidence Interval) 21
Figure 5: Drug Model Diagram of Revatio 26
Figure 6: Revatio, PAH, Global, Sales Estimates ($m), 2005-2020 27
Figure 7: Revatio, PAH, The US, Sales Estimates ($m), 20052017 28
Figure 8: Revatio, PAH, The UK, Sales Estimates ($m), 20052017 29
Figure 9: Revatio, PAH, France, Sales Estimates ($m), 20052017 30
Figure 10: Revatio, PAH, Germany, Sales Estimates ($m), 20052017 31
Figure 11: Revatio, PAH, Italy, Sales Estimates ($m), 20052017 32
Figure 12: Revatio, PAH, Spain, Sales Estimates ($m), 20052017 33
Figure 13: Revatio, PAH, Japan, Sales Estimates ($m), 2008-2020 34
Figure 14: Revatio, PAH, Sales Distribution by Country (%) 2011 35
Figure 15: Drug Model Diagram 38
Figure 16: Patients Approved for the Drug 39

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *